Incidence, Risk factors, and Outcomes of Thromboembolism in Patients with Melanoma Receiving Immune Checkpoint Inhibitors, Chemotherapy, or Targeted Therapy: a SEER-Medicare Analysis. (PubMed, J Thromb Haemost) - Sep 13, 2026 - "ICI, chemotherapy, and targeted therapy are associated with a high incidence of TE; TE is associated with substantial worsening of survival."
Checkpoint inhibition • Journal • Medicare • Reimbursement • US reimbursement • Cardiovascular • Diabetes • Melanoma • Metabolic Disorders • Oncology • Solid Tumor • Venous Thromboembolism
|
|
Alok A Khorana; Long Vu; Siran M Koroukian; Tamara A Sussman
|